BioMarin Pharmaceutical
BioMarin Pharmaceutical
BMRN
NASDAQ
70.60
USD
0.00%
About
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide).
Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia.
Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.5M |
| Three Month Average Volume | 47.4M |
| High Low | |
| Fifty-Two Week High | 99.56 USD |
| Fifty-Two Week Low | 73.675 USD |
| Fifty-Two Week High Date | 14 Dec 2023 |
| Fifty-Two Week Low Date | 30 May 2024 |
| Price and Volume | |
| Current Price | 91.21 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.54% |
| Thirteen Week Relative Price Change | 13.52% |
| Twenty-Six Week Relative Price Change | -4.80% |
| Fifty-Two Week Relative Price Change | -20.34% |
| Year-to-Date Relative Price Change | -20.12% |
| Price Change | |
| One Day Price Change | -0.18% |
| Thirteen Week Price Change | 21.50% |
| Twenty-Six Week Price Change | 4.67% |
| Five Day Price Change | 1.32% |
| Fifty-Two Week Price Change | -0.19% |
| Year-to-Date Price Change | -5.40% |
| Month-to-Date Price Change | 8.16% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 26.25449 USD |
| Book Value Per Share (Most Recent Quarter) | 27.77066 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 23.65161 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 25.34503 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 1.97161 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 12.62677 USD |
| Revenue Per Share (Trailing Twelve Months) | 13.28363 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.875 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 1.32649 USD |
| Normalized (Last Fiscal Year) | 0.98869 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.89252 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 1.35581 USD |
| Including Extraordinary Items (Last Fiscal Year) | 0.875 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 1.32649 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.69364 USD |
| Cash Per Share (Most Recent Quarter) | 6.43192 USD |
| Cash Flow Per Share (Last Fiscal Year) | 1.42757 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 1.86264 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 1.09211 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 1 |
| Cash Flow Revenue (Trailing Twelve Months) | 8 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 11.54% |
| Pretax Margin (Last Fiscal Year) | 7.79% |
| Pretax Margin (5 Year) | 1.27% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 78.72% |
| Gross Margin (Trailing Twelve Months) | 80.07% |
| Gross Margin (5 Year) | 76.30% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 5.52% |
| Operating Margin (Trailing Twelve Months) | 9.15% |
| Operating Margin (5 Year) | 0.64% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 6.93% |
| Net Profit Margin (Trailing Twelve Months) | 9.91% |
| Net Profit Margin (5 Year) | 2.05% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 9.54% |
| Tangible Book Value (5 Year) | 14.37% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 19.61% |
| Revenue Growth (3 Year) | 10.16% |
| Revenue Change (Trailing Twelve Months) | 15.83% |
| Revenue Per Share Growth | 8.44% |
| Revenue Growth (5 Year) | 9.15% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -5.74% |
| Total Debt (5 Year) | 5.54% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 87.66% |
| EPS Change (Trailing Twelve Months) | 215.86% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | 232.51% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 336 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 82 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -135,398,000 |
| Net Debt (Last Fiscal Year) | 13.4M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 7 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 69 |
| PE Normalized (Last Fiscal Year) | 92 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 61 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 502 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 62 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 69 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 12 |
| Long Term Debt to Equity (Most Recent Quarter) | 11 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | 2 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 105 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 70 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 51.6M |
| Free Cash Flow (Trailing Twelve Months) | 212.8M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 22 |
| Total Debt to Equity (Most Recent Quarter) | 21 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 2.54% |
| Return on Assets (Trailing Twelve Months) | 3.76% |
| Return on Assets (5 Year) | 0.71% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 3.51% |
| Return on Equity (Trailing Twelve Months) | 5.10% |
| Return on Equity (5 Year) | 1.01% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 2.93% |
| Return on Investment (Trailing Twelve Months) | 4.29% |
| Return on Investment (5 Year) | 0.81% |